Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 36

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

Efficacy and safety of dexibuprofen (S‑ibuprofen) gel versus placebo for pain relief in patients with acute soft‑tissue contusions, with background paracetamol

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dexibuprofen

Deafness

Recruiting

Safety, Tolerability and Efficacy of Intracochlear SENS-601 in Children with GJB2‑Related Hearing Loss

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:SENS-601

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Engasertib

Effects of metyrapone and hydrocortisone on cardio‑metabolic health and circadian rhythm in patients with mild autonomous cortisol secretion

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone

Efficacy and Safety of Amara‑Tropfen Dilution vs Placebo in Patients with Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Artemisia absinthium, herba REC., ethanol. EXTR. 1:2,3

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Camoteskimab

Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Siplizumab

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium Chloride
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.